Overview

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2017-11-28
Target enrollment:
Participant gender:
Summary
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab
Zoledronic Acid